Peptide Receptor Guide

Introduction

Peptides exert their biological effects by binding to specific receptors on cell surfaces or, less commonly, intracellular targets. Understanding which receptors a peptide activates (or blocks), how selective that interaction is, and what downstream signaling cascades result is essential for interpreting research outcomes, anticipating side effects, and designing rational stacking protocols.

This guide covers the major receptor families relevant to peptide research, the peptides that interact with them, and the pharmacological principles governing these interactions.

Core Receptor Families

GHRH Receptor (GHRH-R)

The growth hormone-releasing hormone receptor is a G-protein coupled receptor (GPCR) expressed primarily on somatotroph cells in the anterior pituitary. Activation stimulates growth hormone (GH) synthesis and secretion through the cAMP/PKA signaling pathway.

Key peptide ligands:

• Sermorelin — a 29-amino acid GHRH analog (GHRH 1-29) that retains full receptor binding activity
• CJC-1295 (with and without DAC) — a modified GHRH analog with enhanced stability
• Tesamorelin — FDA-approved GHRH analog for HIV-associated lipodystrophy

GHRH-R activation produces pulsatile GH release that mirrors physiological secretion patterns. Unlike direct GH administration, GHRH-R agonists preserve negative feedback through somatostatin, maintaining GH within normal physiological ranges Alba et al., 2006.

GHS-R / Ghrelin Receptor (GHS-R1a)

The growth hormone secretagogue receptor (type 1a) is a constitutively active GPCR that serves as the receptor for ghrelin, the "hunger hormone." It is expressed in the hypothalamus, pituitary, and throughout the GI tract. GHS-R1a signals through Gq/11 and activates PLC/IP3/DAG pathways.

Key peptide ligands:

• Ipamorelin — highly selective GHS-R1a agonist with minimal effect on cortisol, prolactin, or ACTH Raun et al., 1998
• GHRP-2 — potent GHS-R1a agonist; also activates corticotroph pathways (elevates cortisol and prolactin at higher doses)
• GHRP-6 — strong GHS-R1a agonist; notable for significant appetite stimulation via ghrelin-mimetic activity
• MK-677 (Ibutamoren) — non-peptide, orally active GHS-R1a agonist; long-acting Nass et al., 2008

Selectivity matters: Ipamorelin's selectivity for GHS-R1a over other pathways is why it produces GH release without the cortisol and prolactin spikes seen with GHRP-2 and GHRP-6. This makes receptor selectivity a critical factor in side effect profiles.

GLP-1 Receptor (GLP-1R)

The glucagon-like peptide-1 receptor is expressed in pancreatic beta cells, the GI tract, CNS, and cardiovascular system. Activation enhances glucose-dependent insulin secretion, slows gastric emptying, suppresses glucagon, and promotes satiety through central mechanisms.

Key peptide ligands:

• Semaglutide — GLP-1R agonist with fatty acid acylation for extended half-life (~7 days)
• Liraglutide — earlier-generation GLP-1R agonist with daily dosing
• Tirzepatide — dual GIP/GLP-1 receptor agonist, representing a new class that activates both incretin receptors simultaneously Frias et al., 2021

GLP-1R agonists have demonstrated cardiovascular benefits beyond glycemic control, including reduced major adverse cardiovascular events (MACE) in large clinical trials Marso et al., 2016.

Melanocortin Receptors (MC1R–MC5R)

The melanocortin receptor family comprises five subtypes with distinct tissue distributions and functions:

Key peptide ligands:

• PT-141 (Bremelanotide) — MC4R agonist; FDA-approved for hypoactive sexual desire disorder. Acts centrally on hypothalamic pathways rather than peripherally Kingsberg et al., 2019
• Melanotan II — non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R); produces tanning (MC1R), appetite suppression (MC3R/MC4R), and sexual arousal (MC4R)
• Melanotan I (Afamelanotide) — MC1R-selective; primarily affects pigmentation without significant MC4R activity

The side effect profiles of melanocortin peptides directly reflect their receptor selectivity. Melanotan II's non-selectivity explains its broad range of effects (tanning, nausea, sexual arousal, appetite suppression), while PT-141's more targeted MC4R activity narrows its effect profile.

TGF-beta Receptors and GHK-Cu

GHK-Cu (copper peptide) operates through a distinct mechanism. Rather than acting as a traditional receptor agonist, GHK-Cu modulates gene expression broadly, including genes in the TGF-beta superfamily pathway. It has been shown to reset gene expression patterns of diseased cells toward healthier profiles, affecting approximately 4,000 human genes Pickart et al., 2015.

GHK-Cu's interactions include:

• Upregulation of TGF-beta signaling (collagen synthesis, wound repair)
• Modulation of integrins (cell adhesion and migration)
• Activation of ubiquitin/proteasome pathways (protein quality control)

Other Relevant Receptor Systems

• CXCR4: Some antimicrobial peptides interact with this chemokine receptor, which plays roles in immune cell trafficking and wound healing
• Opioid receptors: DSIP and certain bioregulator peptides interact with delta opioid pathways
• ACTH receptor (MC2R): Relevant for peptides that affect cortisol production as a side effect (GHRP-2, GHRP-6 at high doses)

Key Pharmacological Concepts

Agonism vs. Antagonism

• Full agonist: Binds the receptor and produces maximal response (e.g., semaglutide at GLP-1R)
• Partial agonist: Binds and activates with submaximal response; can act as a functional antagonist in the presence of a full agonist
• Antagonist: Binds without activating; blocks endogenous ligand access
• Inverse agonist: Reduces constitutive (baseline) receptor activity below basal levels; relevant for constitutively active receptors like GHS-R1a

Receptor Desensitization

Sustained receptor stimulation leads to desensitization — a protective mechanism where cells reduce their responsiveness to ongoing stimulation. This occurs through:

1. Receptor phosphorylation by G-protein coupled receptor kinases (GRKs)
2. Beta-arrestin recruitment, which uncouples the receptor from its G-protein
3. Receptor internalization via clathrin-coated pits
4. Downregulation — reduced receptor synthesis with chronic stimulation

This is why cycling protocols are important for many peptides, particularly GH secretagogues. Continuous GHS-R1a stimulation can lead to blunted GH responses over time Thorner et al., 1997.

Receptor Selectivity and Side Effects

The principle of receptor selectivity is one of the most important concepts in peptide pharmacology. Compare:

• Ipamorelin — highly selective GHS-R1a agonist: GH release with minimal cortisol/prolactin changes
• GHRP-6 — less selective: GH release plus significant appetite stimulation, some cortisol/prolactin elevation
• Melanotan II — non-selective melanocortin agonist: tanning, sexual arousal, nausea, appetite suppression all at once

Greater selectivity generally means a cleaner side effect profile but does not necessarily mean greater efficacy at the target receptor.

Further Reading

• Ipamorelin vs GHRP — Receptor selectivity comparison in GH secretagogues
• Ipamorelin vs CJC-1295 — GHRH-R vs GHS-R complementary mechanisms
• Peptide Cycling Guide — How receptor desensitization informs cycling